Telmivas M 25mg Tablet is a combination of two blood-pressure lowering medicines: Telmisartan and Metoprolol Succinate. Telmisartan is an angiotensin receptor blocker (ARB). It works by blocking the hormone angiotensin thereby relaxing blood vessels. Metoprolol Succinate is a beta blocker which works specifically on the heart to reduce heart rate and lower blood pressure. Together they allow the blood to flow more smoothly and the heart to pump more efficiently.
Taking Metoprolol with alcohol may have additive effects in lowering your blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate.
WEIGH RISKS VS BENEFITS
Telmivas M 25mg Tablet is unsafe to use during pregnancy. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk, for example in life-threatening situations. Please consult your doctor.
Telmivas M 25mg Tablet is probably safe to use during lactation.
Limited human data suggests that the drug does not represent a significant risk to the baby.
Telmivas M 25mg Tablet may make you feel dizzy, sleepy, tired, or decrease alertness. If this happens, do not drive.
Telmivas M 25mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Telmivas M 25mg Tablet is recommended.
Telmivas M 25mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Telmivas M 25mg Tablet may be needed. Please consult your doctor.